Bavarian Nordic Secures Major Contract for Smallpox and Mpox Vaccines

Danish biotech firm to supply 440,000 doses to an undisclosed European country amid rising demand

The contract aligns with Bavarian Nordic's 2024 revenue forecast and strategic goals.
WHO declared mpox a global health emergency following an outbreak in the Democratic Republic of Congo.
Bavarian Nordic can supply up to 10 million doses by the end of next year, with 2 million available this year.
Shares of Bavarian Nordic surged over 11% following the announcement and strong earnings.
The total value of secured contracts in public preparedness is nearing DKK 3 billion.